Warfarin
Warfarin structure
|
Common Name | Warfarin | ||
|---|---|---|---|---|
| CAS Number | 5543-57-7 | Molecular Weight | 308.328 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 515.2±50.0 °C at 760 mmHg | |
| Molecular Formula | C19H16O4 | Melting Point | ≥170ºC | |
| MSDS | Chinese USA | Flash Point | 188.8±23.6 °C | |
| Symbol |
GHS08 |
Signal Word | Danger | |
Use of WarfarinS-(-)-Warfarin is a more potent enantiomer of Warfarin as a vitamin K antagonist with anticoagulant effect[1]. |
| Name | (S)-warfarin |
|---|---|
| Synonym | More Synonyms |
| Description | S-(-)-Warfarin is a more potent enantiomer of Warfarin as a vitamin K antagonist with anticoagulant effect[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 515.2±50.0 °C at 760 mmHg |
| Melting Point | ≥170ºC |
| Molecular Formula | C19H16O4 |
| Molecular Weight | 308.328 |
| Flash Point | 188.8±23.6 °C |
| Exact Mass | 308.104858 |
| PSA | 67.51000 |
| LogP | 3.42 |
| Appearance of Characters | white to pale yellow |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.635 |
| Storage condition | 2-8°C |
| Symbol |
GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360D-H372-H412 |
| Precautionary Statements | P201-P273-P308 + P313 |
| Hazard Codes | T |
| Risk Phrases | 61-48/25-52/53 |
| Safety Phrases | 53-45-61 |
| RIDADR | UN 2811 6.1/PG 1 |
| WGK Germany | 3 |
|
Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes.
J. Thromb. Haemost. 8(12) , 2708-17, (2010) Warfarin, an antagonist of vitamin K, is an oral coumarin anticoagulant widely used to control and prevent thromboembolic disorders. Warfarin is clinically available as a racemic mixture of R- and S-w... |
|
|
Secreted protein profile from HepG2 cells incubated by S(-) and R(+) enantiomers of chiral drug warfarin - An analysis in cell-based system and clinical samples.
Proteomics. Clin. Appl. 4(10-11) , 808-15, (2010) warfarin is a commonly prescribed oral anticoagulant with narrow therapeutic index. It interferes with the vitamin K cycle to achieve anti-coagulating effects. Warfarin has two enantiomers, S(-) and R... |
|
|
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.
Hum. Gene Ther. 20(9) , 975-88, (2009) Oncolytic adenoviruses are anticancer agents that replicate within tumors and spread to uninfected tumor cells, amplifying the anticancer effect of initial transduction. We tested whether coating the ... |
| S-(−)-4-Hydroxy-3-(3-oxo-1-phenybutyl)-2H-1-benzopyran-2-one |
| ATHROMBIN |
| 4-Hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]-2H-chromen-2-one |
| (-)-Warfarin |
| (S)-Warfarin |
| MFCD00272381 |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (S)- |
| Varfine |
| Tintorane |
| 3-a-Phenyl-b-acetylethyl-4-hydroxycoumarin |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]- |
| Warfarin |
| (±)-Warfarin |
| (RS)-Warfarin |
| Warfilone |
| Warcoumin |
| 3-(α-acetonylbenzyl)-4-hydroxycoumarin |
| 3-(α-Phenyl-β-acetylethyl)-4-hydroxycoumarin |
| RODEX |
| 3-(a-acetonylbenzyl)-4-hydroxycoumarin |
| 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one |
| Warfarin,R |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- |
| 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one |
| Antrombin K |
| Coumadin |
| Athrombin-K |
| (S)-(-)-Warfarin |
| Warfarin K |
| EINECS 226-907-3 |